^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH wild-type

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
    Entrez ID:
    3417; 3418
    Related biomarkers:
    Expression
    Mutation
    Others
    1d
    Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors (clinicaltrials.gov)
    P=N/A, N=57, Terminated, Pediatric Brain Tumor Consortium | N=300 --> 57 | Trial completion date: Jul 2028 --> Apr 2026 | Suspended --> Terminated | Trial primary completion date: Jul 2027 --> Apr 2026; The NCI will not extend the PBTC grant beyond March 31, 2026.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Liquid biopsy • Circulating tumor DNA
    |
    IDH wild-type
    2d
    Targeting TNF-α for inhibiting microglia-mediated glioma invasion and therapeutic strategy study (ChiCTR2600120166)
    P=N/A, N=137, The First Affiliated Hospital of the Army Medical University; The First Affiliated Hospital of the Army Medical University
    New trial
    |
    IDH wild-type
    2d
    Exploring the application of WASp activation–mediated enhancement of macrophage phagocytosis in glioblastoma therapy (ChiCTR2600119977)
    P=N/A, N=124, The First Affiliated Hospital of the Army Medical University; The First Affiliated Hospital of the Army Medical University
    New trial
    |
    IDH wild-type
    2d
    Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    IDH wild-type
    |
    MB-101
    3d
    Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes. (PubMed, Cancer Immunol Immunother)
    Predicted peptide presentation was disproportionately associated with a limited subset of HLA class I alleles. Collectively, this study provides a systematically prioritized catalogue of transcriptionally expressed GBM antigen candidates and offers a comparative evaluation of mutation-, expression-, and fusion-derived antigen sources within a unified transcriptome-based framework.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-L • IDH wild-type
    4d
    ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma (clinicaltrials.gov)
    P1, N=94, Recruiting, Mayo Clinic | Trial completion date: Feb 2029 --> May 2029 | Trial primary completion date: Feb 2028 --> May 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    WSD0628
    9d
    Isocitrate Dehydrogenases Idh1 and Idh2 Regulate Pronephric Morphogenesis in Xenopus laevis. (PubMed, Dev Reprod)
    Notably, the oncogenic idh1*R132H variant also rescued the pronephric defects induced by idh1 knockdown, indicating that its neomorphic activity is absent under embryonic metabolic conditions. These findings identify Idh1 and Idh2 as key regulators of pronephric morphogenesis and reveal a developmental function of Idh1 that is distinct from its canonical catalytic role.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type • IDH1 R132
    10d
    Anti-GD2 ADC M3554 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=52, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial primary completion date: Oct 2026 --> Apr 2027
    Trial primary completion date • First-in-human
    |
    IDH wild-type
    10d
    PuMP: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (clinicaltrials.gov)
    P1, N=51, Recruiting, Duke University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    MVR-C5252
    10d
    STAR-GBM: A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Myosin Therapeutics Inc. | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | Trial completion date: Jun 2027 --> Feb 2032 | Initiation date: Nov 2025 --> Apr 2026
    Enrollment open • Phase classification • Trial completion date • Trial initiation date • First-in-human
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type